Jun 1, 2026 06:57AM
May 27, 2026 06:44AM
Apr 29, 2026 04:10PM
Apr 29, 2026 07:00AM
Apr 28, 2026 02:06AM
Apr 28, 2026 02:06AM
Apr 21, 2026 07:03AM Ionis reports positive zilganersen data for Alexander disease
Apr 21, 2026 07:00AM
Mar 25, 2026 03:42PM
Mar 25, 2026 12:24PM
Mar 25, 2026 11:44AM
Mar 25, 2026 10:13AM
Mar 23, 2026 07:00AM
Mar 23, 2026 07:00AM Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
Feb 26, 2026 07:00AM
Feb 26, 2026 07:00AM
Feb 26, 2026 07:00AM
Feb 25, 2026 07:00AM
Feb 4, 2026 07:30AM
Feb 4, 2026 07:30AM
Jul 30, 2025 07:00AM Ionis reports second quarter 2025 financial results and highlights progress on key programs
Jul 21, 2025 07:00AM
Jul 21, 2025 07:00AM
Apr 30, 2025 07:00AM
Apr 7, 2025 06:34AM
Feb 20, 2025 07:03AM
Feb 20, 2025 07:00AM
Feb 20, 2025 05:50AM Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
Feb 19, 2025 02:52PM
Feb 19, 2025 07:00AM
Dec 20, 2024 07:18AM
Nov 6, 2024 07:00AM
Nov 4, 2024 09:45AM
Nov 4, 2024 09:44AM
Sep 26, 2024 06:23AM RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
Aug 1, 2024 07:00AM
Jun 25, 2024 06:55AM
Jun 25, 2024 06:55AM
Mar 13, 2024 03:02PM
Oct 4, 2023 07:00AM
Sep 28, 2023 12:02PM
Aug 9, 2023 07:00AM Ionis reports second quarter 2023 financial results
Jul 31, 2023 07:05AM
Jul 28, 2023 07:05AM
Jul 28, 2023 07:05AM
Jul 10, 2023 07:05AM
Jul 10, 2023 07:05AM
Apr 24, 2023 07:01AM
Apr 24, 2023 07:00AM Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Mar 27, 2023 05:49AM

15,435 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All